These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
446 related articles for article (PubMed ID: 15817912)
61. Biochemical assessment of disease control in acromegaly: reappraisal of the glucose suppression test in somatostatin analogue (SA) treated patients. Christiansen Arlien-Søborg M; Trolle C; Alvarson E; Bæk A; Dal J; Otto Lunde Jørgensen J Endocrine; 2017 Jun; 56(3):589-594. PubMed ID: 28260207 [TBL] [Abstract][Full Text] [Related]
62. Thyroid vascularity is increased in patients with active acromegaly. Bogazzi F; Manetti L; Bartalena L; Gasperi M; Grasso L; Cecconi E; Rago T; Pinchera A; Martino E Clin Endocrinol (Oxf); 2002 Jul; 57(1):65-70. PubMed ID: 12100071 [TBL] [Abstract][Full Text] [Related]
63. Pharmacological therapy for acromegaly: a critical review. Muller AF; Van Der Lely AJ Drugs; 2004; 64(16):1817-38. PubMed ID: 15301564 [TBL] [Abstract][Full Text] [Related]
64. Effectiveness of combined first-line medical treatment in acromegaly with prolactin cosecretion. Biagetti B; Araujo-Castro M; Torre EM; Novoa-Testa I; Cordido F; Corrales EP; Berrocal VR; Guerrero-Pérez F; Vicente A; Percovich JC; Centeno RG; González L; García MDO; Echarri AI; Rodríguez MDM; Novo-Rodríguez C; Calatayud M; Villar-Taibo R; Bernabéu I; Alvarez-Escola C; Valderrama PB; Tenorio-Jiménez C; Galiana PA; Moreno EV; Molero IG; Iglesias P; Blanco C; De Lara FV; de Miguel P; Mezquita EL; Hanzu F; Aldecoa I; Aznar S; Lamas C; Aulinas A; Asla Roca Q; Gracia P; Córdova JMR; Aviles M; Asensio-Wandosel D; Sampedro M; Cámara R; Paja M; Ruz-Caracuel I; Fajardo-Montañana C; Asanza EC; Martinez-Saez E; Marazuela M; Puig-Domingo M Eur J Endocrinol; 2024 Jun; 190(6):458-466. PubMed ID: 38771697 [TBL] [Abstract][Full Text] [Related]
65. Treatment of acromegaly. Holdaway IM Horm Res; 2004; 62 Suppl 3():79-92. PubMed ID: 15539805 [TBL] [Abstract][Full Text] [Related]
66. Long-lasting lowering of serum growth hormone and prolactin levels by single and repetitive cabergoline administration in dopamine-responsive acromegalic patients. Ferrari C; Paracchi A; Romano C; Gerevini G; Boghen M; Barreca A; Fortini P; Dubini A Clin Endocrinol (Oxf); 1988 Nov; 29(5):467-76. PubMed ID: 2908102 [TBL] [Abstract][Full Text] [Related]
67. Medical Therapy of Acromegaly in Germany 2019 - Data from the German Acromegaly Registry. Quinkler M; Petroff D; Knappe UJ; Schopohl J; Tönjes A; Schmid SM Exp Clin Endocrinol Diabetes; 2021 Mar; 129(3):216-223. PubMed ID: 32604431 [TBL] [Abstract][Full Text] [Related]
68. Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm. Clemmons DR; Chihara K; Freda PU; Ho KK; Klibanski A; Melmed S; Shalet SM; Strasburger CJ; Trainer PJ; Thorner MO J Clin Endocrinol Metab; 2003 Oct; 88(10):4759-67. PubMed ID: 14557452 [TBL] [Abstract][Full Text] [Related]
69. Effect of transsphenoidal surgery on sleep apnoea in acromegaly. Sze L; Schmid C; Bloch KE; Bernays R; Brändle M Eur J Endocrinol; 2007 Mar; 156(3):321-9. PubMed ID: 17322492 [TBL] [Abstract][Full Text] [Related]
73. Real-world value of cabergoline in the treatment of acromegaly. Shimon I Best Pract Res Clin Endocrinol Metab; 2024 Jul; 38(4):101887. PubMed ID: 38443225 [TBL] [Abstract][Full Text] [Related]
74. Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly. Heron I; Thomas F; Dero M; Gancel A; Ruiz JM; Schatz B; Kuhn JM J Clin Endocrinol Metab; 1993 Mar; 76(3):721-7. PubMed ID: 8095269 [TBL] [Abstract][Full Text] [Related]
75. Management of acromegaly: is there a role for primary medical therapy? Bush ZM; Vance ML Rev Endocr Metab Disord; 2008 Mar; 9(1):83-94. PubMed ID: 18163213 [TBL] [Abstract][Full Text] [Related]
76. IGF-1 levels may increase paradoxically with dopamine agonist treatment for prolactinomas. Akirov A; Greenman Y; Glaser B; S'chigol I; Mansiterski Y; Eizenberg Y; Shraga-Slutzky I; Shimon I Pituitary; 2018 Aug; 21(4):406-413. PubMed ID: 29728863 [TBL] [Abstract][Full Text] [Related]
77. Increasing frequency of combination medical therapy in the treatment of acromegaly with the GH receptor antagonist pegvisomant. Strasburger CJ; Mattsson A; Wilton P; Aydin F; Hey-Hadavi J; Biller BMK Eur J Endocrinol; 2018 Apr; 178(4):321-329. PubMed ID: 29371335 [TBL] [Abstract][Full Text] [Related]
79. Changes in metabolic parameters and cardiovascular risk factors after therapeutic control of acromegaly vary with the treatment modality. Data from the Bicêtre cohort, and review of the literature. Briet C; Ilie MD; Kuhn E; Maione L; Brailly-Tabard S; Salenave S; Cariou B; Chanson P Endocrine; 2019 Feb; 63(2):348-360. PubMed ID: 30397873 [TBL] [Abstract][Full Text] [Related]
80. Age, GH/IGF-1 levels, tumor volume, T2 hypointensity, and tumor subtype rather than proliferation and invasion are all reliable predictors of biochemical response to somatostatin analogue therapy in patients with acromegaly: A clinicopathological study. Durmuş ET; Atmaca A; Kefeli M; Çalışkan S; Mete O; Aslan K; Fidan M; Çolak R; Durmuş B Growth Horm IGF Res; 2022 Dec; 67():101502. PubMed ID: 36115256 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]